1. De Braekeleer, E, Douet-Guilbert, N, Guardiola, P, Ochoa, C, De Braekeleer, M. 2012. Acute lymphoblastic leukemia associated with RCSD1-ABL1 novel fusion gene has a distinct gene expression profile from BCR-ABL1 fusion. In Leukemia, 27, 1422-4. doi:10.1038/leu.2012.332. https://pubmed.ncbi.nlm.nih.gov/23168614/
2. Park, Hanla A, Edelmann, Dominic, Canzian, Federico, Newcomb, Polly A, Chang-Claude, Jenny. 2023. Genome-wide study of genetic polymorphisms predictive for outcome from first-line oxaliplatin-based chemotherapy in colorectal cancer patients. In International journal of cancer, 153, 1623-1634. doi:10.1002/ijc.34663. https://pubmed.ncbi.nlm.nih.gov/37539667/
3. Li, Yan, Zhang, Qin, Shao, Haigang. 2024. Chemotherapy vs. "TKI + immunotherapy" in treatment of B-cell acute lymphoblastic leukemia harboring the RCSD1::ABL2 fusion gene. In Annals of hematology, 103, 3257-3259. doi:10.1007/s00277-024-05816-7. https://pubmed.ncbi.nlm.nih.gov/38809455/
4. Inokuchi, Koiti, Wakita, Satoshi, Hirakawa, Tsuneaki, Yamaguchi, Hiroki, Dan, Kazuo. 2011. RCSD1-ABL1-positive B lymphoblastic leukemia is sensitive to dexamethasone and tyrosine kinase inhibitors and rapidly evolves clonally by chromosomal translocations. In International journal of hematology, 94, 255-260. doi:10.1007/s12185-011-0910-z. https://pubmed.ncbi.nlm.nih.gov/21863287/
5. De Braekeleer, Etienne, Douet-Guilbert, Nathalie, Rowe, David, Férec, Claude, De Braekeleer, Marc. 2011. ABL1 fusion genes in hematological malignancies: a review. In European journal of haematology, 86, 361-71. doi:10.1111/j.1600-0609.2011.01586.x. https://pubmed.ncbi.nlm.nih.gov/21435002/
智鼠故事 
